Literature DB >> 16721864

Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates.

David Davis1, Helen Donners, Betty Willems, Michel Ntemgwa, Tine Vermoesen, Guido van der Groen, Wouter Janssens.   

Abstract

The aim of the study was to determine if sensitive and resistant human immunodeficiency virus type 1 (HIV-1) subtype B primary isolates have different neutralization kinetics. Neutralization assays were undertaken where either the time allowed for virus to react with antibodies or the subsequent period of this mixture's exposure to target cells were varied. The relative neutralization sensitivity/resistance is a reproducible property of the isolates. In a minority of combinations, the titre falls exponentially for as long as the free virions are exposed to antibody. In the remainder, neutralization kinetics shows deviations which may be attributed to events occurring after the virus-antibody mixture is added to the target cells: significant neutralization with minimal exposure of the free virions to antibody; a plot where reduction in virus titre is parallel to the duration of the incubation phase of the assay. Neutralization rate constants are similar for primary HIV-1 SF33, HIV-1 SF162, and HIV-1 89.6, reaching 5 x 10(5)-1 x 10(6)/M sec for the monoclonal antibody IgG1 b12. However, although increased antibody levels produced greater reductions in virus titre the rate of neutralization was not proportional to the antibody concentration. Neutralization of either the free virion or cell-associated virus does not correlate with the resistance/sensitivity of primary subtype B isolates. The target cells play an active role, so that in designing neutralization assays with primary isolates of HIV-1, events following the virus-antibody complex binding to the cell surface have to be taken into consideration. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721864     DOI: 10.1002/jmv.20635

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.

Authors:  Sunita S Balla-Jhagjhoorsingh; Betty Willems; Liesbeth Heyndrickx; Leo Heyndrickx; Katleen Vereecken; Wouter Janssens; Michael S Seaman; Davide Corti; Antonio Lanzavecchia; David Davis; Guido Vanham
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

2.  Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

Authors:  Simon H Bridge; Sally A Sharpe; Mike J Dennis; Stuart D Dowall; Brian Getty; Donald S Anson; Michael A Skinner; James P Stewart; Tom J Blanchard
Journal:  Virol J       Date:  2011-09-07       Impact factor: 4.099

3.  Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.

Authors:  David Davis; Wim Koornstra; Daniella Mortier; Zahra Fagrouch; Ernst J Verschoor; Jonathan L Heeney; Willy M J M Bogers
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

4.  Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

Authors:  Davide Corti; Johannes P M Langedijk; Andreas Hinz; Michael S Seaman; Fabrizia Vanzetta; Blanca M Fernandez-Rodriguez; Chiara Silacci; Debora Pinna; David Jarrossay; Sunita Balla-Jhagjhoorsingh; Betty Willems; Maria J Zekveld; Hanna Dreja; Eithne O'Sullivan; Corinna Pade; Chloe Orkin; Simon A Jeffs; David C Montefiori; David Davis; Winfried Weissenhorn; Aine McKnight; Jonathan L Heeney; Federica Sallusto; Quentin J Sattentau; Robin A Weiss; Antonio Lanzavecchia
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

5.  In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.

Authors:  David Davis; Wim Koornstra; Zahra Fagrouch; Ernst J Verschoor; Jonathan L Heeney; Willy M J M Bogers
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.